Clinical Trials
26 trialsTesting the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
National Institutes of Health Clinical Center (CC)
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
National Institutes of Health Clinical Center (CC)
Vaccine Response With NT-I7
National Institutes of Health Clinical Center (CC)
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
National Cancer Institute (NCI)
E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia
National Institutes of Health Clinical Center (CC)
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Institutes of Health Clinical Center (CC)
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
National Institutes of Health Clinical Center (CC)
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
National Cancer Institute (NCI)
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
National Institutes of Health Clinical Center (CC)